Cancer immunotherapies
by design

iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for patients.

At iTeos, we specialize in targeted immunotherapies for people living with cancer.

We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies.

Our two clinical stage programs, EOS-448 and Inupadenant, were designed with the aim of having best-in-class properties. We are moving rapidly into late stage clinical trials to explore the full potential of our science.

cancer patient wearing headscarf

Our pipeline

Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations.

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

EOS-448

+ dostarlimab | 1L NSCLC PDL1high

Phase 2, planned

+ dostarlimab | HNSCC

Phase 2, active

+ dostarlimab + CD96 | Advanced Malignancies

Phase 1, active

+ dostarlimab + Inupadenant | Advanced Malignancies

Phase 1, planned

+ Inupadenant | Advanced Malignancies

Phase 2, active

Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma

Phase 2, active

Inupadenant

Monotherapy | High Biomarker

Phase 2, active

+ pembrolizumab | PD-1 Resistant Melanoma

Phase 2, active

+ chemotherapy | 2L Chemo-naive NSCLC

Phase 2, active

EOS-984

IND Enabling Studies

Preclinical, active

Studies with dark backgrounds are active. Studies with light backgrounds are planned.

There has never been a better time to work at iTeos.

As a leading clinical-stage biotech, our innovative science-driven work is fascinating and potentially lifesaving.

Whether it is working in our laboratory or in our offices, you will help people live healthier lives. You will find yourself on the forefront of science, within a high-tech environment where no two days are the same.

scientist working in a lab

Latest press releases

See all press releases